Loading...
Header Logo
Keywords
Last Name
Institution

JENNIFER HSU

TitleAssistant Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
DivisionMedicine-General Medicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Han Y, Wei Y, Yao J, Chu YY, Li CW, Hsu JL, Nie L, Hung MC. Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERa expression in high-grade serous ovarian carcinoma. Am J Cancer Res. 2020; 10(4):1194-1206. PMID: 32368395.
      View in: PubMed
    2. Zhou C, Liu C, Liu W, Chen W, Yin Y, Li CW, Hsu JL, Sun J, Zhou Q, Li H, Hu B, Fu P, Atyah M, Ma Q, Xu Y, Dong Q, Hung MC, Ren N. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway. Theranostics. 2020; 10(10):4627-4643. PMID: 32292519.
      View in: PubMed
    3. Sun L, Li CW, Chung EM, Yang R, Kim YS, Park AH, Lai YJ, Yang Y, Wang YH, Liu J, Qiu Y, Khoo KH, Yao J, Hsu JL, Cha JH, Chan LC, Hsu JM, Lee HH, Yoo SS, Hung MC. Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity. Cancer Res. 2020 Jun 01; 80(11):2298-2310. PMID: 32156778.
      View in: PubMed
    4. Chou CK, Liu YL, Chen YI, Huang PJ, Tsou PH, Chen CT, Lee HH, Wang YN, Hsu JL, Lee JF, Yankeelov TE, Kameoka J, Yeh HC, Hung MC. Digital Receptor Occupancy Assay in Quantifying On- and Off-Target Binding Affinities of Therapeutic Antibodies. ACS Sens. 2020 02 28; 5(2):296-302. PMID: 32073836.
      View in: PubMed
    5. Sun X, Li CW, Wang WJ, Chen MK, Li H, Lai YJ, Hsu JL, Koller PB, Chan LC, Lee PC, Cheng FJ, Yam C, Chen GY, Hung MC. Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma. Am J Cancer Res. 2020; 10(2):564-571. PMID: 32195027.
      View in: PubMed
    6. Chu YY, Yam C, Chen MK, Chan LC, Xiao M, Wei YK, Yamaguchi H, Lee PC, Han Y, Nie L, Sun X, Moulder SL, Hess KR, Wang B, Hsu JL, Hortobagyi GN, Litton J, Chang JT, Hung MC. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. Am J Cancer Res. 2020; 10(2):648-661. PMID: 32195033.
      View in: PubMed
    7. Nie L, Wei Y, Zhang F, Hsu YH, Chan LC, Xia W, Ke B, Zhu C, Deng R, Tang J, Yao J, Chu YY, Zhao X, Han Y, Hou J, Huo L, Ko HW, Lin WC, Yamaguchi H, Hsu JM, Yang Y, Pan DN, Hsu JL, Kleer CG, Davidson NE, Hortobagyi GN, Hung MC. Author Correction: CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2020 Jan 29; 11(1):673. PMID: 31996688.
      View in: PubMed
    8. Nie L, Wei Y, Zhang F, Hsu YH, Chan LC, Xia W, Ke B, Zhu C, Deng R, Tang J, Yao J, Chu YY, Zhao X, Han Y, Hou J, Huo L, Ko HW, Lin WC, Yamaguchi H, Hsu JM, Yang Y, Pan DN, Hsu JL, Kleer CG, Davidson NE, Hortobagyi GN, Hung MC. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun. 2019 11 08; 10(1):5114. PMID: 31704972.
      View in: PubMed
    9. Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms Controlling PD-L1 Expression in Cancer. Mol Cell. 2019 11 07; 76(3):359-370. PMID: 31668929.
      View in: PubMed
    10. Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, Wei Y, Chou CK, Wang SC, Yan M, Tu CY, Hsia TC, Chiang SF, Chao KSC, Wistuba II, Hsu JL, Hortobagyi GN, Hung MC. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell. 2019 08 12; 36(2):168-178.e4. PMID: 31327656.
      View in: PubMed
    11. Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, Zha Z, Lim SO, Lai YJ, Liu C, Liu J, Dong Q, Yang Y, Sun L, Wei Y, Nie L, Hsu JL, Li H, Ye Q, Hassan MM, Amin HM, Kaseb AO, Lin X, Wang SC, Hung MC. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019 07 15; 129(8):3324-3338. PMID: 31305264.
      View in: PubMed
    12. Chen MK, Du Y, Sun L, Hsu JL, Wang YH, Gao Y, Huang J, Hung MC. H2O2 induces nuclear transport of the receptor tyrosine kinase c-MET in breast cancer cells via a membrane-bound retrograde trafficking mechanism. J Biol Chem. 2019 05 24; 294(21):8516-8528. PMID: 30962283.
      View in: PubMed
    13. Han Y, Li CW, Hsu JM, Hsu JL, Chan LC, Tan X, He GJ. Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer. Am J Cancer Res. 2019; 9(4):800-815. PMID: 31106005.
      View in: PubMed
    14. Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, Li CW, Lim SO, Sheng YY, Zhang Y, Li JH, Luo Q, Zheng Y, Zhao Y, Lu L, Jia HL, Hung MC, Dong QZ, Qin LX. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. 2019 09; 68(9):1653-1666. PMID: 30902885.
      View in: PubMed
    15. Han Y, Chen MK, Wang HL, Hsu JL, Li CW, Chu YY, Liu CX, Nie L, Chan LC, Yam C, Wang SC, He GJ, Hortobagyi GN, Tan XD, Hung MC. Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. Am J Cancer Res. 2019; 9(3):608-618. PMID: 30949414.
      View in: PubMed
    16. Li H, Li CW, Li X, Ding Q, Guo L, Liu S, Liu C, Lai CC, Hsu JM, Dong Q, Xia W, Hsu JL, Yamaguchi H, Du Y, Lai YJ, Sun X, Koller PB, Ye Q, Hung MC. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology. 2019 05; 156(6):1849-1861.e13. PMID: 30711629.
      View in: PubMed
    17. Lee PC, Fang YF, Yamaguchi H, Wang WJ, Chen TC, Hong X, Ke B, Xia W, Wei Y, Zha Z, Wang Y, Kuo HP, Wang CW, Tu CY, Chen CH, Huang WC, Chiang SF, Nie L, Hou J, Chen CT, Huo L, Yang WH, Deng R, Nakai K, Hsu YH, Chang SS, Chiu TJ, Tang J, Zhang R, Wang L, Fang B, Chen T, Wong KK, Hsu JL, Hung MC. Targeting PKCd as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. Cancer Cell. 2018 12 10; 34(6):954-969.e4. PMID: 30537515.
      View in: PubMed
    18. Yang Y, Hsu JM, Sun L, Chan LC, Li CW, Hsu JL, Wei Y, Xia W, Hou J, Qiu Y, Hung MC. Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res. 2019 01; 29(1):83-86. PMID: 30514902.
      View in: PubMed
    19. Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018 08 16; 71(4):606-620.e7. PMID: 30118680.
      View in: PubMed
    20. Li CW, Lai YJ, Hsu JL, Hung MC. Activation of phagocytosis by immune checkpoint blockade. Front Med. 2018 Aug; 12(4):473-480. PMID: 30062558.
      View in: PubMed
    21. Sun LL, Yang RY, Li CW, Chen MK, Shao B, Hsu JM, Chan LC, Yang Y, Hsu JL, Lai YJ, Hung MC. Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J Cancer Res. 2018; 8(7):1307-1316. PMID: 30094103.
      View in: PubMed
    22. Yang Y, Li CW, Chan LC, Wei Y, Hsu JM, Xia W, Cha JH, Hou J, Hsu JL, Sun L, Hung MC. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 2018 08; 28(8):862-864. PMID: 29959401.
      View in: PubMed
    23. Yang WH, Cha JH, Xia W, Lee HH, Chan LC, Wang YN, Hsu JL, Ren G, Hung MC. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression. Cancer Res. 2018 07 15; 78(14):3761-3768. PMID: 29789418.
      View in: PubMed
    24. Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, Chen CT, Liao HW, Kuo CW, Khoo KH, Hsu JL, Li CW, Lim SO, Chang SS, Chen YC, Ren GX, Hung MC. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun. 2018 05 15; 9(1):1908. PMID: 29765039.
      View in: PubMed
    25. Wang YN, Lee HH, Chou CK, Yang WH, Wei Y, Chen CT, Yao J, Hsu JL, Zhu C, Ying H, Ye Y, Wang WJ, Lim SO, Xia W, Ko HW, Liu X, Liu CG, Wu X, Wang H, Li D, Prakash LR, Katz MH, Kang Y, Kim M, Fleming JB, Fogelman D, Javle M, Maitra A, Hung MC. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell. 2018 04 09; 33(4):752-769.e8. PMID: 29606349.
      View in: PubMed
    26. Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, Chang SS, Lee HH, Chou CK, Liu YL, Yeh HC, Perillo EP, Dunn AK, Kuo CW, Khoo KH, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Huang TH, Sahin AA, Hortobagyi GN, Yoo SS, Hung MC. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. Cancer Cell. 2018 02 12; 33(2):187-201.e10. PMID: 29438695.
      View in: PubMed
    27. Li Z, Ju X, Lee K, Clarke C, Hsu JL, Abadir E, Bryant CE, Pears S, Sunderland N, Heffernan S, Hennessy A, Lo TH, Pietersz GA, Kupresanin F, Fromm PD, Silveira PA, Tsonis C, Cooper WA, Cunningham I, Brown C, Clark GJ, Hart DNJ. CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma. Haematologica. 2018 04; 103(4):655-665. PMID: 29351987.
      View in: PubMed
    28. Li CW, Lim SO, Hsu JL, Hung MC. Rational combination of immunotherapy for triple negative breast cancer treatment. Chin Clin Oncol. 2017 Oct; 6(5):54. PMID: 29129094.
      View in: PubMed
    29. Chen CT, Chen YC, Du Y, Han Z, Ying H, Bouchard RR, Hsu JL, Hsu JM, Mitcham TM, Chen MK, Sun HL, Chang SS, Li D, Chang P, DePinho RA, Hung MC. A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinoma. Am J Cancer Res. 2017; 7(3):657-672. PMID: 28401019.
      View in: PubMed
    30. Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MC. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017 Jul 15; 23(14):3711-3720. PMID: 28167507.
      View in: PubMed
    31. Hsu JL, Hung MC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016 12; 35(4):575-588. PMID: 27913999.
      View in: PubMed
    32. Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN, Hung MC. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016 Dec 12; 30(6):925-939. PMID: 27866850.
      View in: PubMed
    33. Ju X, Silveira PA, Hsu WH, Elgundi Z, Alingcastre R, Verma ND, Fromm PD, Hsu JL, Bryant C, Li Z, Kupresanin F, Lo TH, Clarke C, Lee K, McGuire H, Fazekas de St Groth B, Larsen SR, Gibson J, Bradstock KF, Clark GJ, Hart DN. The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+-Activated T Cell Population. J Immunol. 2016 12 15; 197(12):4613-4625. PMID: 27837105.
      View in: PubMed
    34. Wang Y, Hsu JM, Kang Y, Wei Y, Lee PC, Chang SJ, Hsu YH, Hsu JL, Wang HL, Chang WC, Li CW, Liao HW, Chang SS, Xia W, Ko HW, Chou CK, Fleming JB, Wang H, Hwang RF, Chen Y, Qin J, Hung MC. Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. Cancer Res. 2016 12 01; 76(23):7049-7058. PMID: 27758883.
      View in: PubMed
    35. Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC. Corrigendum: Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 10 06; 22(10):1192. PMID: 27711065.
      View in: PubMed
    36. Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, Wang Y, Yao J, Lee CC, Wu HJ, Sahin AA, Allison JP, Yu D, Hortobagyi GN, Hung MC. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016 08 30; 7:12632. PMID: 27572267.
      View in: PubMed
    37. Ko HW, Lee HH, Huo L, Xia W, Yang CC, Hsu JL, Li LY, Lai CC, Chan LC, Cheng CC, Labaff AM, Liao HW, Lim SO, Li CW, Wei Y, Nie L, Yamaguchi H, Hung MC. GSK3ß inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget. 2016 Aug 30; 7(35):57131-57144. PMID: 27494834.
      View in: PubMed
    38. Chen YH, Chung CC, Liu YC, Yeh SP, Hsu JL, Hung MC, Su HL, Li LY. Enhancer of Zeste Homolog 2 and Histone Deacetylase 9c Regulate Age-Dependent Mesenchymal Stem Cell Differentiation into Osteoblasts and Adipocytes. Stem Cells. 2016 08; 34(8):2183-93. PMID: 27250566.
      View in: PubMed
    39. Chou CK, Tsou PH, Hsu JL, Lee HH, Wang YN, Kameoka J, Hung MC. Analysis of Individual Signaling Complexes by mMAPS, a Flow-Proteometric System. Curr Protoc Mol Biol. 2016 Apr 01; 114:20.11.1-20.11.22. PMID: 27038387.
      View in: PubMed
    40. Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016 Feb; 22(2):194-201. PMID: 26779812.
      View in: PubMed
    41. Li CW, Xia W, Lim SO, Hsu JL, Huo L, Wu Y, Li LY, Lai CC, Chang SS, Hsu YH, Sun HL, Kim J, Yamaguchi H, Lee DF, Wang H, Wang Y, Chou CK, Hsu JM, Lai YJ, LaBaff AM, Ding Q, Ko HW, Tsai FJ, Tsai CH, Hortobagyi GN, Hung MC. AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Res. 2016 Mar 15; 76(6):1451-62. PMID: 26759241.
      View in: PubMed
    42. Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, Wu Y, Sahin A, Hanash SM, Hortobagyi GN, Hung MC. EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. Cancer Res. 2016 Mar 01; 76(5):1284-96. PMID: 26759242.
      View in: PubMed
    43. Yang CC, LaBaff A, Wei Y, Nie L, Xia W, Huo L, Yamaguchi H, Hsu YH, Hsu JL, Liu D, Lang J, Du Y, Lien HC, Li LY, Deng R, Chan LC, Yao J, Kleer CG, Hortobagyi GN, Hung MC. Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. Am J Transl Res. 2015; 7(6):1009-20. PMID: 26279746.
      View in: PubMed
    44. Sun Y, Ponz-Sarvise M, Chang SS, Chang WC, Chen CH, Hsu JL, Hung MC. Proteasome inhibition enhances the killing effect of BikDD gene therapy. Am J Transl Res. 2015; 7(2):319-27. PMID: 25901200.
      View in: PubMed
    45. Wang YN, Huo L, Hsu JL, Hung MC. Biochemical fractionation of membrane receptors in the nucleus. Methods Mol Biol. 2015; 1234:99-112. PMID: 25304351.
      View in: PubMed
    46. Huo L, Li CW, Huang TH, Lam YC, Xia W, Tu C, Chang WC, Hsu JL, Lee DF, Nie L, Yamaguchi H, Wang Y, Lang J, Li LY, Chen CH, Mishra L, Hung MC. Activation of Keap1/Nrf2 signaling pathway by nuclear epidermal growth factor receptor in cancer cells. Am J Transl Res. 2014; 6(6):649-63. PMID: 25628777.
      View in: PubMed
    47. Chou RH, Wang YN, Hsieh YH, Li LY, Xia W, Chang WC, Chang LC, Cheng CC, Lai CC, Hsu JL, Chang WJ, Chiang SY, Lee HJ, Liao HW, Chuang PH, Chen HY, Wang HL, Kuo SC, Chen CH, Yu YL, Hung MC. EGFR modulates DNA synthesis and repair through Tyr phosphorylation of histone H4. Dev Cell. 2014 Jul 28; 30(2):224-37. PMID: 25073158.
      View in: PubMed
    48. Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, Kuo TT, Kuok QY, Hsu JL, Sung SY, Hung MC, Sher YP. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Res. 2014 Sep 15; 74(18):5229-43. PMID: 25060522.
      View in: PubMed
    49. Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN, Hung MC. Definition of PKC-a, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res. 2014 Sep 01; 74(17):4822-35. PMID: 24970481.
      View in: PubMed
    50. Xie X, Kong Y, Tang H, Yang L, Hsu JL, Hung MC. Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells. Mol Cancer Ther. 2014 Jul; 13(7):1813-25. PMID: 24785255.
      View in: PubMed
    51. Chou CK, Lee HH, Tsou PH, Chen CT, Hsu JM, Yamaguchi H, Wang YN, Lee HJ, Hsu JL, Lee JF, Kameoka J, Hung MC. mMAPS: a flow-proteometric technique to analyze protein-protein interactions in individual signaling complexes. Sci Signal. 2014 Mar 04; 7(315):rs1. PMID: 24595109.
      View in: PubMed
    52. Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, Lim SO, Du Y, Wang Y, Chang WC, Chen CH, Hsu JL, Wu Y, Lam YC, James BP, Liu X, Liu CG, Patel DJ, Hung MC. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature. 2013 May 16; 497(7449):383-7. PMID: 23636329.
      View in: PubMed
    53. Yu YL, Chou RH, Shyu WC, Hsieh SC, Wu CS, Chiang SY, Chang WJ, Chen JN, Tseng YJ, Lin YH, Lee W, Yeh SP, Hsu JL, Yang CC, Hung SC, Hung MC. Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke. EMBO Mol Med. 2013 Apr; 5(4):531-47. PMID: 23526793.
      View in: PubMed
    54. Yamaguchi H, Hsu JL, Chen CT, Wang YN, Hsu MC, Chang SS, Du Y, Ko HW, Herbst R, Hung MC. Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells. Clin Cancer Res. 2013 Feb 15; 19(4):845-54. PMID: 23344263.
      View in: PubMed
    55. Xie X, Li L, Xiao X, Guo J, Kong Y, Wu M, Liu W, Gao G, Hsu JL, Wei W, Hung MC, Xie X. Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models. Mol Cancer Ther. 2012 Sep; 11(9):1915-24. PMID: 22752427.
      View in: PubMed
    56. Nie L, Wu HJ, Hsu JM, Chang SS, Labaff AM, Li CW, Wang Y, Hsu JL, Hung MC. Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. Am J Transl Res. 2012; 4(2):127-50. PMID: 22611467.
      View in: PubMed
    57. Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, Lee DF, Hsu JM, Huo L, Labaff AM, Liu D, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar NS, Wang KK, Wu Y, Wang H, Ajani J, Hung MC. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell. 2012 Mar 20; 21(3):374-87. PMID: 22439934.
      View in: PubMed
    58. Yamaguchi H, Hsu JL, Hung MC. Regulation of ubiquitination-mediated protein degradation by survival kinases in cancer. Front Oncol. 2012; 2:15. PMID: 22649777.
      View in: PubMed
    59. Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL, Chao CH, Yamaguchi H, Yang NK, Ding Q, Wang Y, Lai YJ, LaBaff AM, Wu TJ, Lin BR, Yang MH, Hortobagyi GN, Hung MC. Epithelial-mesenchymal transition induced by TNF-a requires NF-?B-mediated transcriptional upregulation of Twist1. Cancer Res. 2012 Mar 01; 72(5):1290-300. PMID: 22253230.
      View in: PubMed
    60. Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, Li H, Yen CJ, Kuo HP, Lee DF, Lang J, Huo L, Cheng X, Chen YJ, Li CW, Jeng LB, Hsu JL, Li LY, Tan A, Curley SA, Ellis LM, Dubois RN, Hung MC. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest. 2011 Nov; 121(11):4526-36. PMID: 21985787.
      View in: PubMed
    61. Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell. 2011 Sep 13; 20(3):341-56. PMID: 21907925.
      View in: PubMed
    62. Chen CT, Yamaguchi H, Lee HJ, Du Y, Lee HH, Xia W, Yu WH, Hsu JL, Yen CJ, Sun HL, Wang Y, Yeh ET, Hortobagyi GN, Hung MC. Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase. Mol Cancer Ther. 2011 Aug; 10(8):1327-36. PMID: 21610170.
      View in: PubMed
    63. Chang CJ, Chao CH, Xia W, Yang JY, Xiong Y, Li CW, Yu WH, Rehman SK, Hsu JL, Lee HH, Liu M, Chen CT, Yu D, Hung MC. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol. 2011 Mar; 13(3):317-23. PMID: 21336307.
      View in: PubMed
    64. Hsu JL, Weikert MP, Foroozan R. Modified upgaze technique for pupil examination. J Neuroophthalmol. 2010 Dec; 30(4):344-6. PMID: 20842063.
      View in: PubMed
    65. Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochem Biophys Res Commun. 2010 Dec 03; 403(1):103-7. PMID: 21040707.
      View in: PubMed
    66. Cheng X, Xia W, Yang JY, Hsu JL, Lang JY, Chou CK, Du Y, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. Cancer Res. 2010 Oct 01; 70(19):7684-9. PMID: 20841468.
      View in: PubMed
    67. Hsu JL, Haley CM, Foroozan R. Target visual field: a technique to rapidly demonstrate nonorganic visual field constriction. Arch Ophthalmol. 2010 Sep; 128(9):1220-2. PMID: 20837813.
      View in: PubMed
    68. Dong Y, Shi Q, Pai HC, Peng CY, Pan SL, Teng CM, Nakagawa-Goto K, Yu D, Liu YN, Wu PC, Bastow KF, Morris-Natschke SL, Brossi A, Lang JY, Hsu JL, Hung MC, Lee EY, Lee KH. Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues. J Med Chem. 2010 Mar 11; 53(5):2299-308. PMID: 20148565.
      View in: PubMed
    69. Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther. 2009 Aug; 8(8):2375-82. PMID: 19671744.
      View in: PubMed
    70. MacLennan NK, James SJ, Melnyk S, Piroozi A, Jernigan S, Hsu JL, Janke SM, Pham TD, Lane RH. Uteroplacental insufficiency alters DNA methylation, one-carbon metabolism, and histone acetylation in IUGR rats. Physiol Genomics. 2004 Jun 17; 18(1):43-50. PMID: 15084713.
      View in: PubMed
    HSU's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description